Use of M2BPGi in HCC patients with TACE.

Kwon Yong TakBohyun JangSoon Kyu LeeHee Chul NamPil-Soo SungSi Hyun BaeJong Young ChoiSeung Kew YoonJeong Won Jang

Published in: Journal of gastroenterology and hepatology (2021)

Serum M2BPGi level is a useful prognostic indicator of PFS and OS in TACE-treated HCC patients, as well as recurrent cases, which cannot be predicted with the HAP score. The combination of M2BPGi and the HAP score enhances the detection of TACE-preferred patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
patient reported outcomes
patient reported